Shares of ACADIA Pharmaceuticals Inc. (ACAD) are down more than 18 percent in pre-market on Tuesday at $19.71, after its schizophrenia drug candidate failed to meet the primary endpoint in late-stage study.
Topline results from the Phase 3 ADVANCE-2 study showed that pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline on the Negative Symptom Assessment-16 (NSA-16) total score.
The NSA-16 scale is designed to measure change on the wide range of predominant negative symptoms that patients experience, which looks at 16 different items and covers symptoms such as blunted affect, poor socialization and lack of motivation.?
The company said that it does not intend to conduct any further clinical trials with pimavanserin.
ACADIA shares had closed at $2.13, up 2.94 percent on Tuesday. The stock has traded in the range of $17.71 - $33.99 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.